I read it too... but it was from EPGL, not Coopervision! What has Coopervision ever said to suggest such a number? They don't even mention EPGL in conference calls and filings!
If Coopervision's total annual revenues are in the $1B range, how could EPGL ever hope to derive anywhere near that with some potential sliver of sales of just certain products?
The 1.1B number does not remotely reflect reality, IMO!
My guess is <$5M up front and an *undisclosed* royalty for signing over all rights. And that is IF the patented designs ever makes it into an FDA approved and marketed product.
People don't want to hear this, but that is the likely reality of deals like this in my experience. I'll be happy to be proven wrong... but I don't believe that I will be.